For children aged 12 to 15, the FDA has approved the use of a third dosage of the Pfizer Inc (NYSE: PFE) and BioNTech SE BNTX COVID-19 vaccine.
For people aged 12 and up, the interval between primary doses and booster shots has been shortened to 5 months from 6 months.
The third shot has also been approved by the FDA for immunocompromised children aged 5 to 11.
The FDA said it analyzed published data and real-world evidence given by the Israeli Ministry of Health on the safety of booster doses, including data from nearly 6,300 people aged 12 to 15 who got a Pfizer shot.
Price Action: During the market session on the last check Monday, PFE shares were down 3.22 percent at $57.15, and BNTX stock was down 4.97 percent at $245.